@TumorBoardTues Case Conversations_2022

 

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.

MODERATOR

Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

SCHEDULE

#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time. You can join the conversation at https://twitter.com/TumorBoardTues

DateTopicFacultyDisclosuresConversationsSupporter
Tuesday, December 6, 2022Claudin 18.2
AMA Credit
Samuel J. Klempner, MD
Associate Professor
Department of Medicine, Division of Hematology-Oncology
Massachusetts General Cancer Center
Harvard Medical School
Boston, Massachusetts
Samuel J. Klempner, MD
Advisory Board: Daiichi-Sankyo, BMS, Eli Lilly, Exact Sciences, Merck, Mersana
Consulting: Astellas
Stock Ownership: Turning Point Therapeutics
Tuesday, November 29, 2022Bladder Cancer TX Upon Progression
AMA and MOC credit
Posttest rationale
Matthew D. Galsky, MD
Professor of Medicine
Department of Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Jonathan Anker, MD, PhD
Fellow
Department of Hematology/Oncology
Mount Sinai Hospital
New York, New York
Matthew D. Galsky, MD
Advisor:Alligator, AstraZeneca, Basilea, Bristol Myers Squibb, Curis, Dragonfly, EMD Serono, Fujifilm, GSK, Genentech, Janssen, Merck, NuMab, Pfizer, Rappta Therapeutics, SeaGen, Silverback, Urogen

Jonathan Anker, MD, PhD has no real or apparent conflicts to disclose.
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Exelixis, Inc., and Merck Sharp & Dohme Corp.
Tuesday, November 15, 2022
Amivantamab for Lung Cancer
AMA and MOC credit
Posttest rationale
Estelamari Rodriguez, MD, MPH
Assistant Professor of Clinical Medicine
Department of Medical Oncology
Sylvester Comprehensive Cancer Center
University of Miami
Miami, Florida

Samuel Kareff, MD, MPH
Clinical Fellow
Department of Hematology/Oncology
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Estelamari Rodriguez, MD, MPH
Consultant: AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen Oncology
Speaker: Research to Practice, Targeted Oncology

Samuel Kareff, MD, MPH has no real or apparent conflicts to disclose
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Regeneron Pharmaceuticals, Inc. and Sanofi.
Tuesday, November 8, 2022
1st & Subsequent Lines (Challenging Case in I/O in BC
AMA and MOC credit
Posttest rationale
Stephanie L. Graff, MD
Assistant Professor of Medicine
Department of Hematology & Medical Oncology
Warren Alpert Medical School of Brown University
Director of Breast Oncology
Lifespan Cancer Institute
Providence, Rhode Island

Charles Milrod, MD
Fellow
Department of Hematology & Medical Oncology
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Laura Salama, MD
Fellow
Department of Hematology & Medical Oncology
Warren Alpert Medical School of Brown University
Providence, Rhode Island
Stephanie L. Graff, MD
Advisory Board: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Novartis, Pfizer, Seagen

Charles Milrod, MD & Laura Salama, MD have no real or apparent conflicts to disclose
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday, November 1, 2022
ALK Positive NSCLC
AMA and MOC credit
Posttest rationale
Lecia V. Sequist, MD, MPH
Professor
Department of Medicine
Harvard Medical School
Boston, Massachusetts
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Regeneron Pharmaceuticals, Inc. and Sanofi.
Tuesday, October 18, 2022
Early-stage Breast Cancer HER2+
AMA and MOC credit
Posttest rationale
Eleonora Teplinsky, MD
Head, Breast Medical Oncology
Clinical Assistant Professor of Medicine
Icahn School of Medicine at Mount Siani
Valley Health System
Paramus, New Jersey
Eleonora Teplinsky, MD
Medical advisor: FloHealth, Sermo
Advisory board: AstraZeneca
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday, October 11, 2022Biomarker Testing for Patients
AMA and MOC credit
Posttest rationale
Rana R. McKay, MD
Associate Professor
Department of Medicine
University of California San Diego
San Diego, California
Rana R. McKay, MD
Consultant: AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Sorrento, Tempus
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Exelixis, Inc., and Merck Sharp & Dohme Corp.
Monday, October 3, 20223rd Line Treatment NSCLC with EGFR Mutation
AMA and MOC credit
Posttest rationale
Nathan Pennell, MD, PhD, FASCO
Director, Lung Cancer Medical Oncology Program
Cleveland Clinic
Professor, Department of Hematology and Medical Oncology
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio
Nathan Pennell, MD, PhD, FASCO
Consultant: Eli Lilly/LOXO, Genentech, Janssen, Merck, Mirati, Pfizer, Sanofi Genzyme
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Regeneron Pharmaceuticals, Inc. and Sanofi.
Tuesday, September 20, 2022PIK3CA - Metastatic (Stage 4) Breast Cancer
AMA and MOC credit
Posttest rationale
Maryam Lustberg, MD, MPH
Director, Breast Program
Department of Breast Medical Oncology
Yale Cancer Center
Yale University
New Haven, Connecticut

Jasmine S. Sukumar, MD
Assistant Professor
Department of Breast Medical Oncology
MD Anderson Cancer Center
University of Texas
Houston, Texas
Maryam Lustberg, MD, MPH
Consultant: AstraZeneca, Biotheranostics, Novartis, Pfizer, PledPharma, Sanofi Aventis

Jasmine S. Sukumar, MD has no real or apparent conflicts to disclose.
TBT Conversation Part 1

TBT Conversation Part 2
Supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday, September 6, 20221st line NSCLC differentiate PD-1/PD-L1 inhibitors
AMA and MOC credit
Posttest rationale
Narjust Florez (Duma), MD
Associate Director of Cancer Care Equity
Thoracic Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Member of the Faculty
Harvard Medical School
Boston, Massachusetts

Shruti Rajesh Patel, MD
Fellow
Department of Oncology
Stanford Health Care
Stanford, California
Narjust Florez (Duma), MD
Consulting Fees (eg. advisory boards): AstraZeneca, BI Oncology, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Pfizer
Speakers’ Bureaus: Neogenomics

Shruti Rajesh Patel, MD has no real or apparent conflicts to disclose.
TBT Conversation Supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Regeneron Pharmaceuticals, Inc. and Sanofi.
Tuesday,
August 30, 2022
Stage III Unresectable NSCLC
AMA and MOC credit
Posttest Rationale
Hossein Borghaei, DO
Professor & Chief, Thoracic Oncology
Department of Medical Oncology
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania
Hossein Borghaei, DO
Consultant: Amgen, AstraZeneca, Axiom, Beigene, BioNTech, Boehringer Ingelheim, Bristol Myers-Squibb, Daiichi, Da Volterra, EMD-Serono, Genentech, Genmab, Guardant, iTEO, Janssen, Jazz, Lilly, Merck, Mirati, Natera, Novartis, Oncocyte, PharmaMar, Pfizer, Regeneron, Takeda

Advisory Board: Amgen, AstraZeneca, Axiom, Beigene, BioNTech, Boehringer Ingelheim, Bristol Myers-Squibb, Daiichi, Da Volterra, EMD-Serono, Genentech, Genmab, Guardant, iTEO, Janssen, Jazz, Lilly, Merck, Mirati, Natera, Novartis, Oncocyte, PharmaMar, Pfizer, Regeneron, Takeda

Scientific Advisory Board: Nucleai (Stock Options), Inspirna (Formerly Rgenix, Stock Options), Sonnetbio (Stock Options)

Clincal Trial Support: Bristol Myers-Squibb, Lilly

DSMB: CAR T Program, Incyte, Novartis, Takeda, University of Pennsylvania
TBT Conversation Supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Regeneron Pharmaceuticals, Inc. and Sanofi.
Monday,
August 15, 2022
HER2 Low Breast Cancer and ADCs - TDXd
AMA and MOC credit
Posttest Rationale
Hope S. Rugo, MD
Professor of Medicine
University of California San Francisco Comprehensive Cancer Center
San Francisco, California

Laura Huppert, MD
Assistant Professor
Department of Medicine
University of California San Francisco
San Francisco, California
Hope S. Rugo, MD
Clinical Research (to UC Regents Only): AstraZeneca, Astellas, Ayala, Boehringer Ingelheim, Daiichi, Gilead, Lilly, Macrogenics, Merck, Novartis, Pfizer, Polyphor, Roche, Seattle Genetics, Sermonix

Honoraria: Blueprint, Chugai, Puma, NAPO, Samsung

Travel: GE Healthcare

Laura Huppert, MD has no real or apparent conflicts to disclose.
TBT Conversation Part 1

TBT Conversation Part 2
Supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday,
August 9, 2022
Adjuvant Treatment Following Nephrectomy
AMA and MOC credit
Posttest Rationale
Brian Rini, MD
Chief of Clinical Trials
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee
Brian Rini, MD
Consultant: Aravive, AVEO, Bristol Myers-Squibb, Exelixis, Pfizer, Merck

Research Funding (to institution): Aravive, AVEO, Bristol Myers-Squibb, Exelixis, Pfizer, Merck
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Exelixis, Inc., and Merck Sharp & Dohme Corp.
Tuesday,
August 2, 2022
BRCA+ TNBC – PARP inhibitor or I/O in First Line Treatment?
AMA and MOC credit
Posttest Rationale
Aditya Bardia, MD, MPH
Director, Breast Cancer Research
Associate Professor, Harvard Medical School
Attending Physician, Massachusetts General Hospital
Boston, Massachusetts

Arielle J. Medford, MD
Medical Oncology Fellow
Department of Hematology/Oncology
Massachusetts General Hospital
Dana Farber Cancer Institute
Boston, Massachusetts
Aditya Bardia, MD, MPH
Consultant: AstraZeneca, Daiichi Sankyo, Eli Lilly, Foundation Medicine, Genentech, Gilead, Immunomedics, Merck, Novartis, Pfizer, Phillips, Radias Health, Sanofi

Arielle J. Medford, MD has no real or apparent conflicts to disclose.
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday,
July 19, 2022
1st Line Treatment and Management of BRCA Mutated Metastatic Breast Cancer
AMA and MOC credit
Posttest Rationale
Paolo Tarantino, MD
Clinical Research Fellow, Breast Oncology Center
Dana-Farber Cancer Institute
Researcher, European Institute of Oncology
Boston, Massachusetts

Caterina Sposetti, MD
Fellow
Department of Medical Oncology
Università degli Studi di Milano
Resident
Department of Medical Oncology
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Paolo Tarantino, MD
Consulting: AstraZeneca

Speaker: AstraZeneca

Caterina Sposetti, MD has no real or apparent conflicts to disclose.
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday,
July 12, 2022
2nd Line Treatment of EGFR Exon 20 Insertion Lung Cancer
AMA and MOC Credit
Posttest Rationale
Charu Aggarwal, MD, MPH
Associate Director, Penn Center of Precision Medicine
Leslye M. Heisler Associate Professor of Medicine
Department of Medicine/Division of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

Aakash Desai, MD, MPH
Hematology Oncology Fellow
Mayo Clinic
Rochester, Minnesota
Charu Aggarwal, MD, MPH
Consulting: AstraZeneca, BeiGene, Blueprint Genetics, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eisai, Genentech, Janssen, Lilly, Merck, Pfizer, Regeneron/Sanofi, Shionogi, Turning Point Therapeutics

Research Funding (to institution): AstraZeneca/MedImmune, Genentech/Roche, Incyte, Macrogenics, Merck

Aakash Desai, MD, MPH has no real or apparent conflicts to disclose.
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Regeneron Pharmaceuticals, Inc. and Sanofi.
Tuesday,
July 5, 2022
Neo/adjuvant Treatment for BRCA Mutated Early Breast Cancer
AMA and MOC credit
Posttest Rationale
Erika Hamilton, MD
Director
Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Mythili Shastry, PhD
Senior Program Manager
Sarah Cannon Research Institute
Nashville, Tennessee
Erika Hamilton, MD
Research funding (payable to institution only, no personal funds): Abbvie, Acerta Akesobio Amgen, ArQule, Arvinas, AstraZeneca, Australia, Biomedicine, Biotechnology, Black Boehringer Cancer Clovis, Compugen, Curis, CytomX, Daiichi Dana Deciphera, Diamond, eFFECTOR EMD Epigenetics, Farber Fochon, FujiFilm, G1 Genentech/Roche, H3 Harpoon, Health, Hospital, Hutchinson Immunogen, Immunomedics, Infinity Ingelheim, InventisBio, Karyopharm, Labs Leap Lilly, Lycera, Macrogenics, MedImmune, MediPharma, Merck, Mersana, Merus, Millenium, Molecular Novartis, Nucana, Olema, OncoMed, Onconova Orinove, Pfizer, Pharma, Pharmaceuticals, PharmaMar, Plexxicon, Polyphor, Puma Radius Regeneron, Rgenix, Sankyo, SeaGen, Sermonix Serono, Shattuck Silverback StemCentRx, Sutro, Syndax, Syros, Taiho, Takeda, TapImmune, Templates, Tesaro, Therapeutics, Torque, Verastem, Zenith Zymeworks

Consulting/advisory role payments (to institution only, no personal funds accepted): Arvinas, AstraZeneca, Biomedicine, Biotechnology, Black Boehringer CytomX, Daiichi Dantari, Deciphera Diamond, Eisai, Genentech/Roche, H3 Ingelheim, Lilly, Merck, Mersana, Novartis, Pfizer, Pharmaceuticals, Puma Sankyo, Seagen Silverback Therapeutics

Mythili Shastry, PhD has no real or apparent conflicts to disclose.
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday,
June 28, 2022
Early Stage High Risk TNBC Neoadjuvant IO Treatment
AMA and MOC credit
Posttest Rationale
Rebecca A. Shatsky, MD
Associate Professor of Medicine
Scientific Director of Inflammatory and Triple Negative Breast Cancer Program
Department of Hematology-Oncology
UC San Diego Health
La Jolla, California
Rebecca Shatsky, MD
Consultant: Gilead, Sotteria Precision Medicine, The Dedham Group, OncoSec

Institutional Principle Investigator: OncoSec, Phoenix Moleculare Designs, Roche/Genentech

Principle Investigator: Oncternal Therapeutics
TBT Conversation Part 1

TBT Conversation Part 2
Supported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday,
June 14, 2022
Adjuvant Treatment in EGFR Mutated Lung Cancer
AMA and MOC credit
Posttest Rationale
Narjust Florez (Duma), MD
Associate Director of Cancer Care Equity
Thoracic Oncologist
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Member of the Faculty
Harvard Medical School
Boston, Massachusetts

Shruti Rajesh Patel, MD
Fellow
Department of Oncology
Stanford Health Care
Stanford, California
Narjust Florez (Duma), MD
Consulting Fees (eg. advisory boards): AstraZeneca, BI Oncology, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Pfizer
Speakers’ Bureaus: Neogenomics

Shruti Rajesh Patel, MD has no real or apparent conflicts to disclose.
TBT Conversation Part 1

TBT Conversation Part 2
Supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Regeneron Pharmaceuticals, Inc. and Sanofi.
Tuesday,
May 24, 2022
MET Exon 14 Lung Cancer
AMA and MOC credit
Posttest Rationale
Giselle MA Dutcher, MD
Hematology Oncology Fellow
Sylvester Comprehensive Cancer Center
Jackson Memorial Hospital
Miami, Florida

Estelamari Rodriguez, MD, MPH
Assistant Professor of Clinical Medicine, Medical Oncology
Sylvester Comprehensive Cancer Center
University of Miami
Miami, Florida
Giselle MA Dutcher, MD has no real or apparent conflicts to disclose.

Estelamari Rodriguez, MD, MPH
Advisor: Bristol Myers-Squibb, Eli Lilly, Genentech, Janssen Oncology, Novartis

Consultant: AstraZeneca

Speaker: OncLive, Research to Practice
TBT Conversation Part 1

TBT Conversation Part 2
No supporter listed
Tuesday,
May 17, 2022
2nd Line Treatment of HER2+ Breast Cancer
AMA and MOC credit
Posttest Rationale
Paolo Tarantino, MD
Clinical Research Fellow, Breast Oncology Center
Dana-Farber Cancer Institute
Researcher, European Institute of Oncology
Boston, Massachusetts
Paolo Tarantino, MD
Consulting: AstraZeneca

Speaker: AstraZeneca
TBT ConversationSupported by educational grants from AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., and Merck Sharp & Dohme Corp.
Tuesday,
May 10, 2022
Localized advanced CRC
AMA credit only
Flavio Rocha, MD, FACS, FSSO
Clinical Associate Professor of Surgery
University of Washington
Hedinger Chair and Chief of Surgical Oncology, Knight Cancer Institute
Director of Research, Digestive Disease Institute
Associate Medical Director, Floyd and Delores Jones Cancer Institute
Seattle, Washington
Flavio Rocha, MD, FACS, FSSO
Advisory Board: AstraZeneca

Consultant: Medtronic, Oncosil

Research Funding: Gunze
TBT ConversationNo supporter listed
Tuesday,
April 26, 2022
A Rare But Great Opportunity in Gastric Cancer
AMA and MOC credit
Joao Fogacci, MD
Researcher
Molecular Cancer Program
National Cancer Institute
Rio de Janiero, Brazil
Joao Fogacci, MD
Speaker: Bayer, Servier

Advisor: Servier
TBT ConversationNo supporter listed
Tuesday,
April 12, 2022
FGFR Inhibitor in Cholangiocarcinoma
AMA credit only
Wungki Park, MD
Assistant Attending
Department of Medicine, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Wungki Park, MD
Consultant: Aegle, Astellas, Gossamerbio, Merck, Miracogen, Onconics
TBT ConversationNo supporter listed

PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with gastrointestinal (GI) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of colorectal, gastric, esophageal, and biliary tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GI cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underlie the use of targeted entities.

Tumor Board Tuesdays is a bi-weekly, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.

TARGET AUDIENCE

This activity is designed to meet the needs of medical oncologists, physicians assistants, nurse practitioners, interventional radiologists, surgeons, pathologists and other HCPs involved in the treatment and management of patients with solid tumors.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

If you wish to claim credit for your participation in TBT conversations from April 12, 2022 – Present you can do so here: www.integrityce.com/TBTEval

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Tumor Board Tuesday. Integrity Continuing Education, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live material for a maximum of 24.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. 

The faculty/planners listed in the schedule portion of this page reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities.

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Foundation Medicine, Merck
Educational (Unbranded) Program Speaker:
Novartis, Pfizer
Funding to Institution:
Arcus, Merck, Seattle Genetics
Stock Ownership:
Perthera, Inc.

The Integrity Continuing Education, Inc. and Tumor Board Tuesday planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

For optimal performance, the use of Internet Explorer below 8 is not recommended.

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below
Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Exelixis, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck Sharp & Dohme Corp.; Regeneron Pharmaceuticals, Inc. and Sanofi.